Synendos Therapeutics takes in Series A
Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing.
Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination